Long Term Safety Observation of Crizotinib in Chinese NSCLC Population

Stopped The trial is terminated based on business decision, not due to safety concerns or regulatory requirements.

Conditions

• ALK or ROS1-positive NSCLC

Interventions

• DRUG: Crizotinib

Sponsor

Pfizer